• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful treatment of tocilizumab and ivermectin for a patient with ARDS due to COVID-19.

作者信息

Chuang Tzu-Yi, Tsai Ming-Han, Wu Lit-Min, Ho Sung-Jung, Yeh Pu-Sheng, Liu Yi-Lien, Fred Yang Hung-Jen

机构信息

Division of Pulmonary Medicine, Min-Sheng General Hospital, Taoyuan, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.

Division of Critical Care Medicine, Min-Sheng General Hospital, Taoyuan, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.

出版信息

J Microbiol Immunol Infect. 2020 Oct 3;54(1):147-8. doi: 10.1016/j.jmii.2020.09.007.

DOI:10.1016/j.jmii.2020.09.007
PMID:34756359
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7837228/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1536/7837228/2a925adc2cb3/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1536/7837228/2a925adc2cb3/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1536/7837228/2a925adc2cb3/gr1_lrg.jpg

相似文献

1
Successful treatment of tocilizumab and ivermectin for a patient with ARDS due to COVID-19.托珠单抗和伊维菌素成功治疗一名因COVID-19导致急性呼吸窘迫综合征的患者。
J Microbiol Immunol Infect. 2020 Oct 3;54(1):147-8. doi: 10.1016/j.jmii.2020.09.007.
2
Tocilizumab for COVID-19 Acute Respiratory Distress Syndrome: Outcomes Assessment Using the WHO Ordinal Scale.托珠单抗治疗新型冠状病毒肺炎急性呼吸窘迫综合征：使用世界卫生组织序贯量表进行结果评估
Cureus. 2020 Dec 26;12(12):e12290. doi: 10.7759/cureus.12290.
3
Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.托珠单抗治疗 COVID-19 急性呼吸窘迫综合征：两例危重症患者的成功转归。
Immunotherapy. 2020 Oct;12(15):1127-1132. doi: 10.2217/imt-2020-0154. Epub 2020 Jul 14.
4
Effects of Steroids and Tocilizumab on the Immune Response Profile of Patients with COVID-19-Associated ARDS Requiring or Not Veno-Venous Extracorporeal Membrane Oxygenation.类固醇和托珠单抗对需要或不需要静脉-静脉体外膜肺氧合的COVID-19相关急性呼吸窘迫综合征患者免疫反应谱的影响。
Membranes (Basel). 2021 Aug 9;11(8):603. doi: 10.3390/membranes11080603.
5
Repurposing the drug, ivermectin, in COVID-19: toxicological points of view.重新利用药物伊维菌素治疗 COVID-19：毒理学观点。
Eur J Med Res. 2022 Feb 5;27(1):21. doi: 10.1186/s40001-022-00645-8.
6
The Use of High-Dose Corticosteroids Versus Low-Dose Corticosteroids With and Without Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.COVID-19 急性呼吸窘迫综合征中高剂量与低剂量皮质类固醇联合或不联合托珠单抗的应用。
Ann Pharmacother. 2023 Jan;57(1):5-15. doi: 10.1177/10600280221094571. Epub 2022 May 19.
7
Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.托珠单抗治疗 COVID-19 中的“细胞因子风暴综合征”：一例报告。
Acta Med Indones. 2021 Apr;53(2):194-201.
8
Impact of immunosuppressive regimen on ICU acquired pneumonia in critically ill COVID-19.免疫抑制方案对危重症 COVID-19 患者 ICU 获得性肺炎的影响。
Minerva Anestesiol. 2023 Sep;89(9):783-791. doi: 10.23736/S0375-9393.23.17196-3. Epub 2023 May 11.
9
Assessment of Tocilizumab (Humanized Monoclonal Antibody) for Therapeutic Efficacy and Clinical Safety in Patients with Coronavirus Disease (COVID-19).评估托珠单抗（人源化单克隆抗体）治疗新型冠状病毒肺炎（COVID-19）患者的疗效和临床安全性。
Medicina (Kaunas). 2022 Aug 10;58(8):1076. doi: 10.3390/medicina58081076.
10
Early Use of Tocilizumab May Prevent Clinical Deterioration in Select COVID-19 Patients: A Case Series.托珠单抗的早期使用可能预防部分新冠患者的临床病情恶化：病例系列研究
Cureus. 2020 Jul 14;12(7):e9187. doi: 10.7759/cureus.9187.

引用本文的文献

1
Progress in cytokine research for ARDS: A comprehensive review.急性呼吸窘迫综合征细胞因子研究进展：综述
Open Med (Wars). 2024 Oct 28;19(1):20241076. doi: 10.1515/med-2024-1076. eCollection 2024.
2
Novel combination therapy for respiratory diseases of small ruminants: Field studies of over 10 years.小型反刍动物呼吸道疾病的新型联合疗法：超过10年的实地研究。
J Adv Vet Anim Res. 2023 Sep 30;10(3):516-521. doi: 10.5455/javar.2023.j705. eCollection 2023 Sep.
3
Multi-drug Treatment for COVID-19-induced Acute Respiratory Distress Syndrome.

本文引用的文献

1
FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.FDA 批准了具有治疗 SARS-CoV-2（COVID-19）潜力的药物。
Drug Resist Updat. 2020 Dec;53:100719. doi: 10.1016/j.drup.2020.100719. Epub 2020 Jul 15.
2
Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management.早期使用托珠单抗预防 SARS-CoV-2 感染所致成人呼吸衰竭及白细胞介素-6 水平在管理中的应用。
J Med Virol. 2021 Jan;93(1):491-498. doi: 10.1002/jmv.26288. Epub 2020 Jul 15.
3
The COVID-19 Cytokine Storm; What We Know So Far.
新冠病毒病所致急性呼吸窘迫综合征的多药治疗
Turk J Pharm Sci. 2022 Feb 28;19(1):101-103. doi: 10.4274/tjps.galenos.2021.63060.
4
Neurological Involvement in COVID-19 and Potential Mechanisms: A Review.新型冠状病毒肺炎的神经受累情况及潜在机制：综述
Neurocrit Care. 2021 Jun;34(3):1062-1071. doi: 10.1007/s12028-020-01049-4.
《COVID-19 细胞因子风暴：目前我们所了解的》。
Front Immunol. 2020 Jun 16;11:1446. doi: 10.3389/fimmu.2020.01446. eCollection 2020.
4
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.托珠单抗治疗伴有炎症过度反应和急性呼吸衰竭的重症 COVID-19 肺炎：意大利布雷西亚单中心 100 例患者研究。
Autoimmun Rev. 2020 Jul;19(7):102568. doi: 10.1016/j.autrev.2020.102568. Epub 2020 May 3.
5
Treatment options for COVID-19: The reality and challenges.治疗 COVID-19 的选择：现实与挑战。
J Microbiol Immunol Infect. 2020 Jun;53(3):436-443. doi: 10.1016/j.jmii.2020.03.034. Epub 2020 Apr 4.